An Introduction to ER+/HER2- mBC and Current Treatment Options

Now Viewing

EP: 1.An Introduction to ER+/HER2- mBC and Current Treatment Options

EP: 2.Biomarker Testing in Patients With ER+/HER2- mBC

EP: 3.The EMERALD Trial: Elacestrant Mechanism of Action, Study Design, and Outcomes

EP: 4.Key Efficacy Data from Sub-Group Analyses of Patients from the EMERALD Trial

EP: 5.The Future of ER+/HER2- mBC Treatment

Dr. Aditya Bardia: Hello. I'm Aditya Bardia, a breast medical oncologist at Massachusetts General Hospital, Harvard Medical School, Boston.

Today, we'll review potential role of Elacestrant for the treatment of metastatic ER-positive HER2-negative breast cancer. We'll start with an overview of metastatic ER-positive breast cancer, the current landscape, and then review the EMERALD trial with I Elacestrant for metastatic ER-positive breast cancer.

Metastatic ER-positive HER2-negative breast cancer represents a subset of metastatic disease. Metastatic disease refers to patients who have evidence of breast cancer outside of the breast in the bones, liver, or other organs. ER-positive refers to tumors that express estrogen receptors and do not have HER2 amplification so therefore HER2-negative. In general, tissue biopsy is the mainstay for diagnosis of metastatic ER-positive HER2-negative breast cancer. It helps with confirmation of the diagnosis and also evaluation of the receptors.

Endocrine-based therapy is the mainstay of management of metastatic ER-positive HER2-negative breast cancer. It's also the mainstay of management for early ER-positive HER2-negative breast cancer. For metastatic ER-positive HER2-negative metastatic breast cancer, the first line of therapy includes endocrine therapy with a CDK4/6 inhibitor. Usually, it's aromatase inhibitor, but in specific situations fulvestrant is used as the first line endocrine therapy in combination with a CDK4/6 inhibitor. Options for CDK4/6 inhibitors include ribociclib, abemaciclib, and palbociclib. We've seen improvement in overall survival with the use of endocrine therapy plus abema, endocrine therapy plus ribociclib in the first-line setting.